



Original Article

Endothelial antibody levels in the sera of children with autism spectrum disorders

Shahid Bashir^{a,b}, Laila Al-Ayadhi^{b,*}

^a Berenson-Allen Center for Noninvasive Brain Stimulation, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

^b KSU-Autism Research and Treatment Center, Al-Amodi Autism Research Chair, Department of Physiology, Faculty of Medicine, King Saud University, Riyadh, Saudi Arabia

Received March 25, 2014; accepted January 11, 2015

Abstract

Background: The neurobiological basis of autism remains poorly understood. We hypothesized that endothelial antibodies may be associated with the pathophysiology of autism and may predict intellectual/social developmental abnormalities.

Methods: Plasma levels of antiendothelial cell antibodies (AECAs) were measured by enzyme-linked immunosorbent assay in autistic children ($n = 55$) and age-matched healthy controls ($n = 25$).

Results: The serum level of AECAs in children with autism [$n = 55$, 306.4 ± 45.6 pg/mL [mean \pm standard error of the mean (SEM)]] was higher (two-tailed Student t test: $p = 0.05$) than that of healthy controls [$n = 25$, 209.6 ± 24.6 pg/mL (mean \pm SEM)]. Children with severe autism exhibited significantly higher AECAs than healthy controls (diagnoses of autistic children based on the Childhood Autism Rating Scale score, >40) [$n = 20$, 369.6 ± 65.6 pg/mL (mean \pm SEM)] ($p = 0.03$). Disease severity and the Childhood Autism Rating Scale score, which represent stereotyped patterns of behavior in children with autism, were positively correlated ($r^2 = 0.27$, $p = 0.05$).

Conclusion: Elevated AECA serum levels may be implicated in the pathogenesis of autism. However, these data should be interpreted with caution until further investigations are performed using larger sample sizes to determine whether the increase in serum AECA levels is a mere consequence of autism or it plays a pathogenic role in the disease.

Copyright © 2015 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.

Keywords: antiendothelial antibodies; autistic spectrum disorder; autoimmunity; biomarker

1. Introduction

Children with autism exhibit marked deficits in interpersonal social behaviors, abnormal language development, restricted interests, stereotypic/ritualistic behaviors that accompany a particular developmental course, and evidence of developmental delay within the first 3 years of life.^{1–4}

Autoimmunity to the central nervous system may play a pathogenic role in autism spectrum disorder (ASD).^{5–7}

Recently, two lines of research have focused on biological factors in autism. First, excesses of neurotrophins and neuropeptides in infant sera have a predictive value in determining those children who later exhibit disruption of intellectual and or social development.⁶ We have established that one of these factors, brain-derived neurotrophic factor, is elevated in children with autism.⁸ Second, autoantibodies to several antigenic targets are present in the sera of some children with neurodevelopmental disorders.^{9,10} These facts have led us to search for biological markers that may allow earlier detection of autism. In this study, we determined the serum levels of antiendothelial cell antibodies (AECAs) in a group of well-

Conflicts of interest: The authors declare that there are no conflicts of interest related to the subject matter or materials discussed in this article.

* Corresponding author. Dr. Laila Al-Ayadhi, KSU-Autism Research and Treatment Center, Al-Amodi Autism Research Chair, Department of Physiology, King Saud University, PO Box 2925, Riyadh 11461, Saudi Arabia.

E-mail address: ayadh2@gmail.com (L. Al-Ayadhi).

characterized children with autism and a healthy control group.

AECAs are observed in various autoimmune diseases, including systemic lupus erythematosus, scleroderma, mixed connective tissue diseases, hemolytic uremic syndrome, Sjogren's syndrome, rheumatoid arthritis, vasculitis, lupus nephritis, Kawasaki disease, and progressive systemic sclerosis.^{11–15}

However, serum levels of endothelial cells in patients with autism have never been reported. Thus, the aim of this study was to explore a possible role for AECAs in patients with ASD.

2. Methods

2.1. Participants

This case–control study was conducted with 55 children with classic-onset autism. The autistic group consisted of 47 males and eight females. The children were recruited from the Autism Research and Treatment Center, Faculty of Medicine, King Saud University, Riyadh, Saudi Arabia. Their ages ranged between 3 years and 12 years (mean \pm SD = 7.98 \pm 2.59 years). The patients fulfilled the criteria for the diagnosis of autism according to the fourth edition of the *Diagnostic and Statistical Manual of Mental Disorders*.¹ We excluded patients with associated neurological diseases (such as cerebral palsy and tuberous sclerosis) or associated metabolic disorders (e.g., phenylketonuria) because the association of these comorbidities with autism may influence AECA levels. Patients were not receiving any medications.

The control group consisted of 25 age- and sex-matched healthy children (21 males and 4 females). The children's ages ranged between 4 years and 12 years (mean \pm SD = 8.79 \pm 2.89 years). The children were the healthy older siblings of healthy children who attend the Well Baby Clinic, King Khalid University Hospital, Faculty of Medicine, King Saud University, for routine follow-up of their growth parameters. In addition, informed written consent for participation in the study was given by the parents or legal guardians of the participants.

2.2. Study measurements

Clinical evaluation of autistic patients was based on clinical histories provided by caregivers, clinical examinations, and neuropsychiatric assessments. In addition, the degree of autism severity was assessed using the Childhood Autism Rating Scale (CARS),¹⁶ which rates the child on a scale from one to four in each of 15 areas (relating to people; emotional response; imitation; body use; object use; listening response; fear or nervousness; verbal and nonverbal communication; activity level; level and consistency of intellectual response; adaptation to change; visual response; taste, smell, and touch response; and general impressions). According to the scale, children who score 30–36 have mild to moderate autism ($n = 35$), whereas those with scores ranging between 37 points and 60 points have severe autism ($n = 20$).

2.3. Blood samples

After overnight fasting, blood samples (3 mL) were collected from participants of both groups in plain test tubes. Blood samples were allowed to clot and were then centrifuged at 3000 rpm to collect serum samples, which were stored in a freezer at -80°C until they were analytically assayed. A detailed description of the procedure has been provided in our previous reports.^{3,17} To increase accuracy, all samples were analyzed twice in two independent experiments to assess interassay variations and ensure the reproducibility of the observed results ($p > 0.05$).

2.4. Assessment of serum AECAs

Levels of AECAs were measured using a commercially available sandwich enzyme immunoassay (enzyme-linked immunosorbent assay) kit from Cusabio Biotech Co., Ltd (Wuhan, China). No significant cross-reactivity or interference was observed.

2.5. Statistical analysis

The results were analyzed using the commercially available software package Statview (Abacus Concepts, Inc., Berkeley, CA, USA). The data are presented as the mean \pm standard error of the mean (SEM). The Mann–Whitney U test was used for comparisons between data. Spearman's rank correlation coefficient " r " was used to determine the relationship between variables. For all tests, $p < 0.05$ was considered significant. The receiver operating characteristic curve is a plot of sensitivity versus 1-specificity at different cutoff values of the studied variable. The uppermost left point represents the best cutoff value (based on the highest sensitivity with the lowest false-positive results of the studied marker) to differentiate between the two groups under study. If the area under the curve is > 0.5 , the variable is able to differentiate between the two groups; the closer this area to 1, the better its differentiating capacity. The best cutoff value of serum AECAs was 254 pg/mL, with the area under the curve being 0.64, indicating that plasma AECA was a good differentiating marker between patients and controls at this cutoff value.

3. Results

The general characteristics of the study participants and the results of the AECA levels are depicted in Table 1. Patients exhibited significantly higher serum AECA levels [$n = 55$, 306.4 \pm 45.6 pg/mL (mean \pm SEM)] ($p = 0.05$, Fig. 1) than did normal controls [$n = 25$, 209.6 \pm 24.6 pg/mL (mean \pm SEM)]. Increased serum AECA levels were observed in 63% (41/55) of autistic children.

There was a significant difference between normal controls and patients with severe autism (autism diagnoses made on the bases of CARS scores of >40) [$n = 20$, 369.6 \pm 65.6 pg/mL (mean \pm SEM)] ($p = 0.03$). However, there was no significant difference between the serum AECA levels of children with

Table 1
Serum levels of AECAs in autistic children and their relationship with autism severity.

	AECAs (pg/mL)	<i>p</i>
Healthy children (<i>n</i> = 25)	209 ± 24.6	
Patients with autism (<i>n</i> = 55)	306.4 ± 45.6	<0.05
Patients with mild to moderate autism (<i>n</i> = 35)	270 ± 61	
Patients with severe autism (<i>n</i> = 20)	369.6 ± 65.6	<0.03

AECA = antiendothelial cell antibody.

mild to moderate autism and those with severe autism (*p* = 0.16; Fig. 2).

There was a positive correlation between disease severity and the CARS score, which represents stereotyped patterns of behavior in children with autism ($r^2 = 0.27, p = 0.05$; Fig. 3).

There was no significant difference between the serum AECAs of male and female autistic patients (*p* = 0.72). Serum AECA levels of autistic patients exhibited no significant correlations with the ages of autistic children (*p* = 0.64).

4. Discussion

We observed significantly elevated AECA serum levels in autistic children compared with a control group of healthy children. Although caution should be exercised in the interpretation of our data, our results suggest a potential role for AECAs in this neurodevelopmental disorder.

Studies have identified autoantibodies to endothelial cells and nuclei in children with autism, idiopathic mental retardation, and epilepsy, but not in healthy control individuals or those with non-neurologic diseases.^{18–22} Several immunologic studies report T-cell dysfunction or abnormal numbers of T-cells in a proportion of autistic patients.^{6,21–23}

In some studies, autoantibodies are not specific to autism. For example, Todd et al²⁴ observed anti-brain IgG autoantibodies, determined by dot blot analysis, that were nonspecific and present in sera from both normal individuals and depressed patients. Cockwell et al²⁵ suggested that endothelial




Fig. 1. Serum levels of endothelial proteins in controls and autistic children. Differences in anti-endothelial cell serum antibody levels between autistic children and healthy controls were statistically significant (*p* = 0.05). AECA = antiendothelial cell antibody.




Fig. 2. Serum levels of AECA in controls and autistic children (mild to moderate and severe conditions based on the CARS score). AECA = antiendothelial cell antibody; CARS = Childhood Autism Rating Scale.

cell activation is defined as “quantitative changes” in the expression levels of specific gene products (i.e., proteins), which in turn endow endothelial cells with new functional capacities. Endothelial cell antigens can be constitutively expressed and/or modulated by either cytokines or cryptic means. In addition, antigen determinants for AECAs may also include molecules that adhere to the endothelium. An alternative mechanism by which AECAs could act as a trigger in the pathogenesis of some diseases may involve complement cytotoxicity and/or antibody-dependent cellular cytotoxicity.^{26–29}

In this study, we measured high mean AECAs in the sera of children with autism compared with healthy controls. Some investigators have reported that endothelial cell activation can be induced by AECAs. Phenotypic changes in the endothelium can be due, in part, to the induction of interleukin (IL)-1 synthesis or other mediators (i.e., IL-1, IL-2, IL-4, IL-6, IL-8, and Macrophage Inflammatory Proteins (MIP)-1).³⁰

There may be a variety of autoantibodies in individuals with autism. The presence of these autoantibodies may be a secondary marker of disease rather than directly pathogenic.




Fig. 3. Relationship between the serum levels of AECA in autistic children and the CARS score. AECA = antiendothelial cell antibody; CARS = Childhood Autism Rating Scale.

To our knowledge, no one has looked prospectively at autoantibodies in a large cohort of children. Irrespective of whether these autoantibodies are of direct etiological relevance, the presence of a marker of disease in ASDs may be important to help determine the time of onset of these devastating disorders. Other autoimmune diseases have both specific and nonspecific autoantibodies.

The chief caveats of our report are the small sample size and its cross-sectional design. We were only able to observe associations, not predictions or causation. Another limitation of our report is that adaptive behavior was not assessed in the control individuals. Therefore, whether levels of AECA factors may be associated with behavioral features in healthy individuals remains to be established. These caveats notwithstanding, we have demonstrated an alteration of the endothelial cell environment in autism characterized by a clear imbalance of important AECAs.

The knowledge resulting from autoimmunity research has direct clinical relevance to the overall health and recovery of autistic children. Our findings provide preliminary, direct evidence of altered AECAs in patients with ASD, which may contribute to the early pathogenesis of ASD, offer valuable biomarkers, point to novel therapeutic development for autism, and offer a novel approach to immunotherapy with the use of natural immunomodulators.

Acknowledgments

SB was supported by the Deanship of Scientific Research grant no. (RGP-216). LA was financially supported by King Saud University, through National Plan for Science, Technology (NPST), Vice Deanship of Research Chairs and by the National Plan for Science, Technology and Innovation (MAARIFAH), King Abdulaziz City for Science and Technology, Kingdom of Saudi Arabia, award number (12-MED2463-02).

The authors would like to thank the Department of Pharmacology, Faculty of Medicine, for hosting the Autism Research & Treatment Center Lab. facility.

References

- American Psychiatric Association. *Diagnostic and statistical manual-text revision (DSM-IV-TR TM)*. Washington, DC: American Psychiatric Association; 2000.
- Fombonne E. Epidemiology of pervasive developmental disorders. *Pediatr Res* 2009;**65**:591–8.
- Mostafa GA, Al-Ayadhi LY. Increased serum levels of anti-ganglioside M1 auto-antibodies in autistic children: relation to the disease severity. *J Neuroinflammation* 2011;**8**:39–45.
- Kriegelstein K, Suter-Crazzolaro C, Fischer WH, Unsicker K. TGF-beta superfamily members promote survival of midbrain dopaminergic neurons and protect them against MPP+ toxicity. *EMBO J* 1995;**14**:736–42.
- Singh VK. Immunotherapy for brain disease and mental illnesses. *Prog Drug Res* 1991;**48**:129–46.
- Singh VK. Neuro-immunopathogenesis in autism. In: Berczi I, Reginald M, Gorczynski RM, editors. *New foundation of biology*. Amsterdam: Elsevier BV Press; 2001. p. 443–54.
- Singh VK. Cytokine regulation in autism. In: Kronfol Z, editor. *Cytokines and mental health*. Boston, MA: Kluwer Academic Publishers; 2003. p. 369–83.
- Singh VK. Rehabilitation of autism by immune modulation therapy. *J Special Educ Rehabil* 2004;**3–4**:161–78.
- Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. *Clin Sci Lond* 2005;**109**:227–41.
- Yasuhara T, Shingo T, Date I. The potential role of vascular endothelial growth factor in the central nervous system. *Rev Neurosci* 2004;**15**:293–307.
- Fulzele S, Pillai A. Decreased VEGF mRNA expression in the dorsolateral prefrontal cortex of schizophrenia subjects. *Schizophr Res* 2009;**115**:372–3.
- Balboni G, Pedrabissi L, Molteni M, Villa S. Discriminant validity of the Vineland scales: score profiles of individuals with mental retardation and a specific disorder. *Am J Ment Retard* 2001;**106**:162–72.
- Blumberg HP, Wang F, Chepenik LG, Kalmar JH, Edmiston E, Duman RS, et al. Influence of vascular endothelial growth factor variation on human hippocampus morphology. *Biol Psychiatry* 2008;**64**:901–3.
- Nicolson R, DeVito TJ, Vidal CN, Sui Y, Hayashi KM, Drost DJ, et al. Detection and mapping of hippocampal abnormalities in autism. *Psychiatry Res* 2006;**148**:11–21.
- Renaudineau Y, Grunebaum E, Krause I, Praprotnik S, Revelen R, Youinou P, et al. Antiendothelial cell antibodies in systemic sclerosis: increased sensitivity using different endothelial cell substrates and association with other autoantibodies. *Autoimmunity* 2001;**33**:171–9.
- Schopler E, Bourgondien MEV, Love SR, Wellman GJ. *Childhood autism rating scale*. 2nd ed. (CARS-2). Riyadh: Pearson; 2010.
- Al-Ayadhi LY. Relationship between sonic hedgehog protein, brain-derived neurotrophic factor and oxidative stress in autism spectrum disorders. *Neurochem Res* 2012;**37**:394–400.
- Warren RP, Foster A, Margaretten NC. Reduced natural killer cell activity in autism. *J Am Acad Child Adolesc Psychiatry* 1987;**26**:333–5.
- Warren RP, Cole P, Odell JD, Pingree CB, Warren WL, White E, et al. Detection of maternal antibodies in infantile autism. *J Am Acad Child Adolesc Psychiatry* 1990;**29**:873–7.
- Warren RP, Margaretten NC, Pace NC, Foster A. Immune abnormalities in patients with autism. *J Autism Dev Disord* 1986;**16**:189–97.
- Warren RP, Burger RA, Odell D, Torres AR, Warren WL. Decreased plasma concentrations of the C4B complement protein in autism. *Arch Pediatr Adolesc Med* 1994;**148**:180–3.
- Warren RP, Yonk J, Burger RW, Odell D, Warren WL. DR-positive T cells in autism: association with decreased plasma levels of the complement C4B protein. *Neuropsychobiology* 1995;**31**:53–7.
- Singh VK, Fudenberg HH, Emerson D, Coleman M. Immunodiagnosis and immunotherapy in autistic children. *Ann N Y Acad Sci* 1988;**540**:602–4.
- Todd RD, Hickok JM, Anderson GM, Cohen DJ. Antibrain antibodies in infantile autism. *Biol Psychiatry* 1988;**23**:644–7.
- Cockwell P, Tse WY, Savage COS. Activation of endothelial cells in thrombosis and vasculitis. *Scand J Rheumatol* 1997;**26**:145–50.
- Ahmed SS, Tan FK, Arnett FC, Jin L, Geng YJ. Induction of apoptosis and fibrillin 1 expression in human dermal endothelial cells by scleroderma sera containing anti-endothelial cell antibodies. *Arthritis Rheum* 2006;**54**:2250–62.
- Bordron A, Dueymes M, Levy Y, Jamin C, Leroy JP, Piette JC, et al. The binding of some human antiendothelial cell antibodies induces endothelial cell apoptosis. *J Clin Invest* 1998;**101**:2029–35.
- Fullerton DA, Eisenach JH, Friese RS, Agrafojo J, Sheridan BC, McIntyre Jr RC. Impairment of endothelial-dependent pulmonary vasorelaxation after mesenteric ischemia/reperfusion. *Surgery* 1996;**120**:879–84.
- Gabrielli A, Di Loreto C, Taborro R, Candela M, Sambo P, Nitti C, et al. Immunohistochemical localization of intracellular and extracellular associated TGF beta in the skin of patients with systemic sclerosis (scleroderma) and primary Raynaud's phenomenon. *Clin Immunol Immunopathol* 1993;**68**:340–52.
- Dinarelo CA, Cannon JG, Mier JW, Bernheim HA, LoPreste G, Lynn DL, et al. Multiple biological activities of human recombinant interleukin 1. *J Clin Invest* 1986;**77**:1734–9.